(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Exhibit | Description of Document | |||||||
99.1 | ||||||||
104 | Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document. |
VERTEX PHARMACEUTICALS INCORPORATED | |||||
(Registrant) | |||||
Date: May 6, 2024 | /s/ Jonathan Biller | ||||
Jonathan Biller | |||||
Executive Vice President, Chief Legal Officer |
Current FY 2024 | Previous FY 2024 | ||||||||||
Total product revenues | Unchanged | $10.55 to $10.75 billion | |||||||||
Combined GAAP R&D, Acquired IPR&D and SG&A expenses (2) | Unchanged | $4.9 to $5.1 billion | |||||||||
Combined Non-GAAP R&D, Acquired IPR&D and SG&A expenses (2) | Unchanged | $4.3 to $4.4 billion | |||||||||
Non-GAAP effective tax rate | Unchanged | 20% to 21% |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Product revenues, net | $ | 2,690.6 | $ | 2,374.8 | |||||||
Costs and expenses: | |||||||||||
Cost of sales | 342.6 | 266.9 | |||||||||
Research and development expenses | 789.1 | 742.6 | |||||||||
Acquired in-process research and development expenses | 76.8 | 347.1 | |||||||||
Selling, general and administrative expenses | 342.7 | 241.1 | |||||||||
Change in fair value of contingent consideration | (0.1) | (1.9) | |||||||||
Total costs and expenses | 1,551.1 | 1,595.8 | |||||||||
Income from operations | 1,139.5 | 779.0 | |||||||||
Interest income | 181.2 | 122.6 | |||||||||
Interest expense | (10.4) | (11.4) | |||||||||
Other (expense) income, net | (31.2) | 1.3 | |||||||||
Income before provision for income taxes | 1,279.1 | 891.5 | |||||||||
Provision for income taxes | 179.5 | 191.7 | |||||||||
Net income | $ | 1,099.6 | $ | 699.8 | |||||||
Net income per common share: | |||||||||||
Basic | $ | 4.26 | $ | 2.72 | |||||||
Diluted | $ | 4.21 | $ | 2.69 | |||||||
Shares used in per share calculations: | |||||||||||
Basic | 258.2 | 257.4 | |||||||||
Diluted | 261.1 | 260.3 |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
TRIKAFTA/KAFTRIO | $ | 2,483.6 | $ | 2,096.7 | |||||||
Other CF products | 207.0 | 278.1 | |||||||||
Product revenues, net | $ | 2,690.6 | $ | 2,374.8 |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
GAAP cost of sales | $ | 342.6 | $ | 266.9 | |||||||
Stock-based compensation expense | (1.8) | (1.9) | |||||||||
Intangible asset amortization expense | (5.0) | — | |||||||||
Non-GAAP cost of sales | $ | 335.8 | $ | 265.0 | |||||||
GAAP research and development expenses | $ | 789.1 | $ | 742.6 | |||||||
Stock-based compensation expense | (119.4) | (76.3) | |||||||||
Acquisition-related costs | — | (2.8) | |||||||||
Non-GAAP research and development expenses | $ | 669.7 | $ | 663.5 | |||||||
Acquired in-process research and development expenses | $ | 76.8 | $ | 347.1 | |||||||
GAAP selling, general and administrative expenses | $ | 342.7 | $ | 241.1 | |||||||
Stock-based compensation expense | (70.7) | (44.2) | |||||||||
Non-GAAP selling, general and administrative expenses | $ | 272.0 | $ | 196.9 | |||||||
Combined non-GAAP R&D, Acquired IPR&D and SG&A expenses | $ | 1,018.5 | $ | 1,207.5 | |||||||
GAAP other (expense) income, net | $ | (31.2) | $ | 1.3 | |||||||
Decrease (increase) in fair value of strategic investments | 27.0 | (6.4) | |||||||||
Non-GAAP other expense, net | $ | (4.2) | $ | (5.1) | |||||||
GAAP provision for income taxes | $ | 179.5 | $ | 191.7 | |||||||
Tax adjustments (1) | 81.6 | 22.7 | |||||||||
Non-GAAP provision for income taxes | $ | 261.1 | $ | 214.4 |
GAAP effective tax rate | 14.0 | % | 21.5 | % | |||||||
Non-GAAP effective tax rate | 17.4 | % | 21.3 | % |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
GAAP operating income | $ | 1,139.5 | $ | 779.0 | |||||||
Stock-based compensation expense | 191.9 | 122.4 | |||||||||
Intangible asset amortization expense | 5.0 | — | |||||||||
Decrease in fair value of contingent consideration | (0.1) | (1.9) | |||||||||
Acquisition-related costs | — | 2.8 | |||||||||
Non-GAAP operating income | $ | 1,336.3 | $ | 902.3 | |||||||
GAAP net income | $ | 1,099.6 | $ | 699.8 | |||||||
Stock-based compensation expense | 191.9 | 122.4 | |||||||||
Intangible asset amortization expense | 5.0 | — | |||||||||
Decrease (increase) in fair value of strategic investments | 27.0 | (6.4) | |||||||||
Decrease in fair value of contingent consideration | (0.1) | (1.9) | |||||||||
Acquisition-related costs | — | 2.8 | |||||||||
Total non-GAAP adjustments to pre-tax income | 223.8 | 116.9 | |||||||||
Tax adjustments (1) | (81.6) | (22.7) | |||||||||
Non-GAAP net income | $ | 1,241.8 | $ | 794.0 | |||||||
Net income per diluted common share: | |||||||||||
GAAP | $ | 4.21 | $ | 2.69 | |||||||
Non-GAAP | $ | 4.76 | $ | 3.05 | |||||||
Shares used in diluted per share calculations: | |||||||||||
GAAP and Non-GAAP | 261.1 | 260.3 |
March 31, 2024 | December 31, 2023 | ||||||||||
Assets | |||||||||||
Cash, cash equivalents and marketable securities | $ | 10,171.3 | $ | 11,218.3 | |||||||
Accounts receivable, net | 1,793.2 | 1,563.4 | |||||||||
Inventories | 813.1 | 738.8 | |||||||||
Prepaid expenses and other current assets | 511.1 | 623.7 | |||||||||
Total current assets | 13,288.7 | 14,144.2 | |||||||||
Property and equipment, net | 1,172.8 | 1,159.3 | |||||||||
Goodwill and intangible assets, net | 1,922.9 | 1,927.9 | |||||||||
Deferred tax assets | 1,963.0 | 1,812.1 | |||||||||
Operating lease assets | 312.9 | 293.6 | |||||||||
Long-term marketable securities | 4,381.4 | 2,497.8 | |||||||||
Other long-term assets | 875.7 | 895.3 | |||||||||
Total assets | $ | 23,917.4 | $ | 22,730.2 | |||||||
Liabilities and Shareholders' Equity | |||||||||||
Accounts payable and accrued expenses | $ | 3,147.3 | $ | 3,020.2 | |||||||
Other current liabilities | 648.6 | 527.2 | |||||||||
Total current liabilities | 3,795.9 | 3,547.4 | |||||||||
Long-term finance lease liabilities | 361.5 | 376.1 | |||||||||
Long-term operating lease liabilities | 359.8 | 348.6 | |||||||||
Other long-term liabilities | 853.6 | 877.7 | |||||||||
Shareholders' equity | 18,546.6 | 17,580.4 | |||||||||
Total liabilities and shareholders' equity | $ | 23,917.4 | $ | 22,730.2 | |||||||
Common shares outstanding | 258.3 | 257.7 |
Document and Entity Information Document |
May 06, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | May 06, 2024 |
Entity Registrant Name | VERTEX PHARMACEUTICALS INC / MA |
Entity Central Index Key | 0000875320 |
Amendment Flag | false |
Entity Incorporation, State or Country Code | MA |
Entity File Number | 000-19319 |
Entity Tax Identification Number | 04-3039129 |
Entity Address, Address Line One | 50 Northern Avenue |
Entity Address, City or Town | Boston |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02210 |
City Area Code | 617 |
Local Phone Number | 341-6100 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, $0.01 Par Value Per Share |
Trading Symbol | VRTX |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
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end
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